ArticleESC heart failure2023
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Peripartum Cardiomyopathy: Current Insights into Pathogenesis and Clinical Management: A Narrative Review.Journal of clinical medicine · 2026Review
- Society for Maternal-Fetal Medicine Consult Series #73: Diagnosis and management of right and left heart failure during pregnancy and postpartum.Pregnancy (Hoboken, N.J.) · 2025Article
- Pregnancy-Associated Cardiomyopathy in a Late-Diagnosed Partial Hydatidiform Mole: A Case Report.Case reports in obstetrics and gynecology · 2025Article
- The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality?Reviews in endocrine & metabolic disorders · 2024Review
- Pharmacological interventions for peripartum cardiomyopathy.The Cochrane database of systematic reviews · 2024Article
- Transcriptomic and metabolomic dissection of skeletal muscle of crossbred Chongming white goats with different meat production performance.BMC genomics · 2024Article
- Peripartum cardiomyopathy in patients with psychiatric disorders successfully treated with bromocriptine: Two case reports.Journal of cardiology cases · 2024Article
- Bromocriptine: does this drug of Parkinson's disease have a role in managing cardiovascular diseases?Annals of medicine and surgery (2012) · 2024Review
- Connecting the Dots: Exploring the Interplay Between Preeclampsia and Peripartum Cardiomyopathy.Journal of pregnancy · 2024Review
- Immunometric and functional measurement of endogenous vasoinhibin in human sera.Frontiers in endocrinology · 2024Article
- Primary takotsubo syndrome with recurrent prolactinoma.Journal of cardiology cases · 2023Article
- Article
- Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsPeripartum cardiomyopathy (PPCM) is a rare heart disease, occurring in previously heart-healthy women during the last month of pregnancy or the first months after delivery due to left ventricular (LV) systolic dysfunction. A common pathomechanistic pathway of PPCM includes increased oxidative stress and the subsequent generation of a cleaved prolactin fragment (16 kDa PRL), which promotes the onset of heart failure (HF) in a microRNA (miR)-146a-dependent manner. Inhibition of prolactin secretion with the dopamine D2 receptor (D2R) agonist bromocriptine combined with standard HF therapy supports cardiac recovery. This study examined whether treatment with the more selective D2R agonist cabergoline prevents HF development in an experimental PPCM mouse model and might be used as an alternative treatment regime for PPCM. METHODS AND
resultsPostpartum (PP) female PPCM-prone mice with a cardiomyocyte restricted STAT3-deficiency (αMHC-Cre
conclusionsIn the experimental PPCM mouse model, the selective D2R agonist cabergoline prevents the onset of postpartum HF similar to bromocriptine. In PPCM patients, cabergoline treatment was safe and effective as all patients fully recovered. Cabergoline might serve as a promising alternative to bromocriptine. However, these findings are based on experimental data and a small case series and thus have to be interpreted with caution and should be validated in a larger clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.